# Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

> **NCT00394472** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 244 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** AZD3355

## Key facts

- **NCT ID:** NCT00394472
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2013-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394472, "Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00394472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*